Medicenna Therapeutics Total Debt vs. Cash Per Share
| MDNA Stock | CAD 1.79 0.09 4.79% |
For Medicenna Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Medicenna Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Medicenna Therapeutics Corp utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Medicenna Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Medicenna Therapeutics Corp over time as well as its relative position and ranking within its peers.
Medicenna |
Medicenna Therapeutics Cash Per Share vs. Total Debt Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Medicenna Therapeutics's current stock value. Our valuation model uses many indicators to compare Medicenna Therapeutics value to that of its competitors to determine the firm's financial worth. Medicenna Therapeutics Corp is rated top company in total debt category among its peers. It also is considered to be number one stock in cash per share category among its peers . The ratio of Total Debt to Cash Per Share for Medicenna Therapeutics Corp is about 16,798,795 . At this time, Medicenna Therapeutics' Cash Per Share is very stable compared to the past year. Comparative valuation analysis is a catch-all model that can be used if you cannot value Medicenna Therapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Medicenna Therapeutics' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Medicenna Total Debt vs. Competition
Medicenna Therapeutics Corp is rated top company in total debt category among its peers. Total debt of Health Care industry is now estimated at about 16.96 Million. Medicenna Therapeutics totals roughly 13.94 Million in total debt claiming about 82% of equities under Health Care industry.
Medicenna Cash Per Share vs. Total Debt
Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Medicenna Therapeutics |
| = | 13.94 M |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Medicenna Therapeutics |
| = | 0.83 X |
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.
Medicenna Cash Per Share Comparison
Medicenna Therapeutics is currently under evaluation in cash per share category among its peers.
Medicenna Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Medicenna Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Medicenna Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Medicenna Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Medicenna Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 19 K | 18.1 K | |
| Operating Income | -19.7 M | -18.7 M | |
| Net Loss | -25.5 M | -24.2 M | |
| Income Before Tax | -25.5 M | -24.2 M | |
| Total Other Income Expense Net | -5.8 M | -5.5 M | |
| Net Loss | -9 M | -9.5 M | |
| Net Loss | -25.5 M | -24.2 M | |
| Income Tax Expense | -10.4 M | -9.9 M | |
| Net Interest Income | 1.2 M | 1.3 M | |
| Interest Income | 1.2 M | 1.2 M | |
| Change To Netincome | -5.8 M | -5.5 M | |
| Net Loss | (0.37) | (0.38) | |
| Income Quality | 0.64 | 1.28 | |
| Net Loss | (0.18) | (0.17) |
Medicenna Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Medicenna Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Medicenna Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Medicenna Therapeutics' important profitability drivers and their relationship over time.
Use Medicenna Therapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Medicenna Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Medicenna Therapeutics will appreciate offsetting losses from the drop in the long position's value.Medicenna Therapeutics Pair Trading
Medicenna Therapeutics Corp Pair Trading Analysis
The ability to find closely correlated positions to Medicenna Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Medicenna Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Medicenna Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Medicenna Therapeutics Corp to buy it.
The correlation of Medicenna Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Medicenna Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Medicenna Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Medicenna Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Medicenna Therapeutics position
In addition to having Medicenna Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Utilities ETFs Thematic Idea Now
Utilities ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Utilities ETFs theme has 13 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Utilities ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Medicenna Stock
To fully project Medicenna Therapeutics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Medicenna Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Medicenna Therapeutics' income statement, its balance sheet, and the statement of cash flows.